Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer
NCT ID: NCT04113096
Last Updated: 2019-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
104 participants
INTERVENTIONAL
2018-10-01
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
American Ginseng for the Prevention of Moderate-severe Fatigue in Breast Cancer Patients
NCT03730298
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
NCT04298333
O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors
NCT00002604
Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
NCT01612910
Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer
NCT00033345
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast Cancer Stage IV
Stage IV Breast Cancer: Dibenzyl trisulphide capsules (20mg once daily)/6 months
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Stage IV Breast Cancer Placebo
20 mg once daily for 6 months
Colon Cancer Stage IV
Stage IV Colon Cancer:Dibenzyl trisulphide capsules (20 mg one daily for 6 months
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Stage IV: Colon Cancer Placebo
20 mg once daily for 6 months
Cervical Cancer Stage IV
Stage IV Cancer of the Cervix: Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Cervical Cancer Stage IV Placebo
20 mg once daily for 6 months
Cancer of the Prostate Stage IV
Stage IV Prostate cancer:Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Cancer of the Prostate Placebo
20 mg once daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Dibenzyl trisulphide capsules
20 mg once daily for 6 months
Stage IV Breast Cancer Placebo
20 mg once daily for 6 months
Stage IV: Colon Cancer Placebo
20 mg once daily for 6 months
Cervical Cancer Stage IV Placebo
20 mg once daily for 6 months
Cancer of the Prostate Placebo
20 mg once daily for 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented histologic evidence of cancer
* Staged as stage IV
* World Health Organization (WHO) Performance Status of between 0 and 2
Exclusion Criteria
* Pregnant women
* Children 0 - 12 years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of The West Indies
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
LAD Williams
Role: PRINCIPAL_INVESTIGATOR
University of the West Indies, Mona
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medial Sciences
Kingston, , Jamaica
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECP 250 - 15/16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.